Testicular Cancer

Overview

Journal Nat Rev Dis Primers

Specialty General Medicine

Date 2018 Oct 7

PMID 30291251

Citations 202

Authors

Liang Cheng

Peter Albers

Daniel M Berney

Darren R Feldman

Gedske Daugaard

Timothy Gilligan

Leendert H J Looijenga

Affiliations

Soon will be listed here.

Abstract

Testicular cancer is the most common malignancy among men between 14 and 44 years of age, and its incidence has risen over the past two decades in Western countries. Both genetic and environmental factors contribute to the development of testicular cancer, for which cryptorchidism is the most common risk factor. Progress has been made in our understanding of the disease since the initial description of carcinoma in situ of the testis in 1972 (now referred to as germ cell neoplasia in situ), which has led to improved treatment options. The combination of surgery and cisplatin-based chemotherapy has resulted in a cure rate of >90% in patients with testicular cancer, although some patients become refractory to chemotherapy or have a late relapse; an improved understanding of the molecular determinants underlying tumour sensitivity and resistance may lead to the development of novel therapies for these patients. This Primer provides an overview of the biology, epidemiology, diagnosis and current treatment guidelines for testicular cancer, with a focus on germ cell tumours. We also outline areas for future research and what to expect in the next decade for testicular cancer.

Citing Articles

A review of the carcinogenic potential of human papillomavirus (HPV) in urological cancers.

Zolfi E, Khaleghi Mehr F, Emtiazi N, Moradi Y Virol J. 2025; 22(1):53.

PMID: 40022189 PMC: 11871667. DOI: 10.1186/s12985-025-02682-1.

Fertility Preservation in More than 7000 Male Patients: A Single-Center, Tertiary Care Registry Study over 30 Years.

Graziani A, Grande G, Martin M, Sorio D, Finocchi F, Corro S Cancers (Basel). 2025; 17(4).

PMID: 40002282 PMC: 11852800. DOI: 10.3390/cancers17040689.

Mirvetuximab Soravtansine Induces Potent Cytotoxicity and Bystander Effect in Cisplatin-Resistant Germ Cell Tumor Cells.

Kucerova L, Fekiacova A, Udvorkova N, Malcharkova P, Blahova V, Jochova S Cells. 2025; 14(4).

PMID: 39996761 PMC: 11853988. DOI: 10.3390/cells14040287.

A 37-Year-Old Man with Multifocal Bilateral Malignant Testicular Large-Cell Calcifying Sertoli Cell Tumors Presenting as Painless Testicular Masses.

Dohmen L, Pani M, Marchettini P, Devos F Am J Case Rep. 2025; 26:e945910.

PMID: 39943671 PMC: 11833513. DOI: 10.12659/AJCR.945910.

Global burden and risk factors of male cancers from 1990 to 2021, with forecasts to 2040.

Zhang Y, Wang P, Jia Z, Zheng Z, Wang J, Liang H Sci Rep. 2025; 15(1):5123.

PMID: 39934217 PMC: 11814104. DOI: 10.1038/s41598-025-88392-8.

References

Siegel R, Miller K, Jemal A . Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1):7-30. DOI: 10.3322/caac.21442. View

Ghazarian A, Kelly S, Altekruse S, Rosenberg P, McGlynn K . Future of testicular germ cell tumor incidence in the United States: Forecast through 2026. Cancer. 2017; 123(12):2320-2328. PMC: 5629636. DOI: 10.1002/cncr.30597. View

Trabert B, Chen J, Devesa S, Bray F, McGlynn K . International patterns and trends in testicular cancer incidence, overall and by histologic subtype, 1973-2007. Andrology. 2014; 3(1):4-12. PMC: 4410839. DOI: 10.1111/andr.293. View

Fitzmaurice C, Allen C, Barber R, Barregard L, Bhutta Z, Brenner H . Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2016; 3(4):524-548. PMC: 6103527. DOI: 10.1001/jamaoncol.2016.5688. View

Berney D, Looijenga L, Idrees M, Oosterhuis J, Rajpert-De Meyts E, Ulbright T . Germ cell neoplasia in situ (GCNIS): evolution of the current nomenclature for testicular pre-invasive germ cell malignancy. Histopathology. 2016; 69(1):7-10. DOI: 10.1111/his.12958. View

Moch H, Cubilla A, Humphrey P, Reuter V, Ulbright T . The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur Urol. 2016; 70(1):93-105. DOI: 10.1016/j.eururo.2016.02.029. View

Cheng L, Lyu B, Roth L . Perspectives on testicular germ cell neoplasms. Hum Pathol. 2016; 59:10-25. DOI: 10.1016/j.humpath.2016.08.002. View

Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K . Guidelines on Testicular Cancer: 2015 Update. Eur Urol. 2015; 68(6):1054-68. DOI: 10.1016/j.eururo.2015.07.044. View

Oldenburg J, Fossa S, Nuver J, Heidenreich A, Schmoll H, Bokemeyer C . Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013; 24 Suppl 6:vi125-32. DOI: 10.1093/annonc/mdt304. View

10.

Hanna N, Einhorn L . Testicular cancer--discoveries and updates. N Engl J Med. 2014; 371(21):2005-16. DOI: 10.1056/NEJMra1407550. View

11.

Hanna N, Einhorn L . Testicular cancer: a reflection on 50 years of discovery. J Clin Oncol. 2014; 32(28):3085-92. DOI: 10.1200/JCO.2014.56.0896. View

12.

Tandstad T, Kollmannsberger C, Roth B, Jeldres C, Gillessen S, Fizazi K . Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable Neoplasm. J Clin Oncol. 2017; 35(31):3525-3528. PMC: 5791831. DOI: 10.1200/JCO.2017.73.4723. View

13.

Feldman D, Bosl G, Sheinfeld J, Motzer R . Medical treatment of advanced testicular cancer. JAMA. 2008; 299(6):672-84. DOI: 10.1001/jama.299.6.672. View

14.

Chovanec M, Hanna N, Cary K, Einhorn L, Albany C . Management of stage I testicular germ cell tumours. Nat Rev Urol. 2016; 13(11):663-673. DOI: 10.1038/nrurol.2016.164. View

15.

Fung C, Sesso H, Williams A, Kerns S, Monahan P, Zaid M . Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy. J Clin Oncol. 2017; 35(11):1211-1222. PMC: 5455601. DOI: 10.1200/JCO.2016.70.3108. View

17.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

18.

Znaor A, Lortet-Tieulent J, Jemal A, Bray F . International variations and trends in testicular cancer incidence and mortality. Eur Urol. 2013; 65(6):1095-106. DOI: 10.1016/j.eururo.2013.11.004. View

19.

Ghazarian A, Trabert B, Devesa S, McGlynn K . Recent trends in the incidence of testicular germ cell tumors in the United States. Andrology. 2014; 3(1):13-8. PMC: 4342271. DOI: 10.1111/andr.288. View

20.

Daugaard G, Gundgaard M, Mortensen M, Agerbaek M, Holm N, Rorth M . Surveillance for stage I nonseminoma testicular cancer: outcomes and long-term follow-up in a population-based cohort. J Clin Oncol. 2014; 32(34):3817-23. DOI: 10.1200/JCO.2013.53.5831. View

21.

Mortensen M, Lauritsen J, Gundgaard M, Agerbaek M, Holm N, Christensen I . A nationwide cohort study of stage I seminoma patients followed on a surveillance program. Eur Urol. 2014; 66(6):1172-8. DOI: 10.1016/j.eururo.2014.07.001. View